World-Pharmacists-Day-Insert
X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Centhaquine

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Lyfaquin

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 20, 2020

            Details:

            Lyfaquin® increases blood pressure and cardiac output by augmenting venous blood return to the heart and enhancing tissue blood perfusion by arterial dilatation (sympatholytic function due to central alpha-2A adrenergic stimulation).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Centhaquine

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 14, 2020

            Details:

            Centhaquine's pivotal phase III study in India in hypovolemic shock demonstrated a transformational improvement over standard of care in increasing blood pressure and reducing blood lactate levels.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Dexamethasone

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Guggenheim Securities

            Deal Size: $21.7 million Upfront Cash: Undisclosed

            Deal Type: Public Offering February 20, 2020

            Details:

            EyePoint intends to use the net proceeds of the offering to continue to fund the commercialization and expand the access of DEXYCU® and YUTIQ® and for general corporate purposes.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Dexamethasone

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Vision Center Network of America

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement February 18, 2020

            Details:

            The agreement will enable VCNA physicians to incorporate DEXYCU into their surgical protocols for treating ocular inflammation associated with cataract surgery.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Dexamethasone

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Ocumension Therapeutics

            Deal Size: $14.0 million Upfront Cash: $2.0 million

            Deal Type: Licensing Agreement February 03, 2020

            Details:

            Ocumension will receive exclusive rights to develop and commercialize the product in Mainland China, Hong Kong, Macau and Taiwan.